IL4 and Alzheimer disease: Selective targeting of the JAK/STAT pathway allows for the control of multiple cytokines involved in AD pathogenesis, such as IL4, 13, 31, 22 and TSLP rather than blocking a single inflammatory interleukin, such as with monoclonal antibodies.